Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix (NASDAQ:FLGT)February 27, 2026
Share Facebook Twitter LinkedIn Pinterest Email Vaxart GAAP EPS of -$0.11 beats by $0.07, revenue of $2.1M beats by $2M
Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix (NASDAQ:FLGT)February 27, 2026
